FOR46

Phase 2

KYNTRA BIO, INC. (KYNB)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

KYNBPhase 2$29M

FOR46 Phase 2 Est. Readout

FOR46• Metastatic Castration-resistant Prostate Cancer44

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

3 competitors in Metastatic Castration-resistant Prostate Cancer

LLY[Lu-177]-PNT2002

Phase 3

XNCRvudalimab monotherapy

Drug Information

Target Indication

Metastatic Castration-resistant Prostate Cancer

Clinical Trial

NCT05011188

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

KYNB

KYNTRA BIO, INC.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOXPhase 3

Pancreatic Cancer Non-resectable

Epoetin AlfaPhase 3

Anemia in End Stage Renal Disease

SEPO®Phase 3

Chemotherapy Induced Anemia

RoxadustatPhase 3

Anemia Associated With End Stage Renal Disease (ESRD)

FG-4592Phase 3

Anemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts